NCT05945485View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

May 26, 2026

Study Completion Date

May 26, 2026

Conditions
Influenza
Interventions
BIOLOGICAL

DCVC H1 HA mRNA vaccine

A modified nucleoside messenger RNA (mRNA) vaccine encoding the full length HA of influenza A/California/07/2009 (H1N1) encapsulated in lipid nanoparticle (LNP) composed of ionizable lipid, DSPC, cholesterol, and PEG lipid for delivery

BIOLOGICAL

Quadrivalent Recombinant Seasonal Influenza Vaccine

The vaccine contains recombinant hemagglutinin (HA) proteins from four influenza viruses, expressed using a baculovirus vector. These HA proteins are produced in a continuous insect cell line.

OTHER

Sodium Chloride, 0.9%

0.9% Sodium Chloride Injection

Trial Locations (1)

52242

University of Iowa - Infectious Disease Clinic, Iowa City

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT05945485 - A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults | Biotech Hunter | Biotech Hunter